SGHT Stock Price, Sight Sciences, Inc. Quote, Chart

Market Summary

USD5.34-0.47

Market Closed

-8.09%

SGHT Stock Price

View Fullscreen

SGHT RSI Chart

SGHT Valuation

Market Cap

265.7M

Price/Earnings (Trailing)

-4.85

Price/Sales (Trailing)

3.26

EV/EBITDA

-3.53

Price/Free Cashflow

-6.58

SGHT Price/Sales (Trailing)

SGHT Profitability

EBT Margin

-67.04%

Return on Equity

-50.16%

Return on Assets

-35.21%

Free Cashflow Yield

-15.19%

SGHT Fundamentals

SGHT Revenue

Revenue (TTM)

81.5M

Rev. Growth (Yr)

2.34%

Rev. Growth (Qtr)

2.74%

SGHT Earnings

Earnings (TTM)

-54.8M

Earnings Growth (Yr)

4.49%

Earnings Growth (Qtr)

-52.46%

Breaking Down SGHT Revenue

Last 7 days

-0.6%

Last 30 days

-0.7%

Last 90 days

29.6%

Trailing 12 Months

-46.7%

How does SGHT drawdown profile look like?

SGHT Financial Health

Current Ratio

13.01

Debt/Equity

0.31

Debt/Cashflow

-1.17

SGHT Investor Care

Shares Dilution (1Y)

2.67%

Diluted EPS (TTM)

-1.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	81.5M	0	0	0
2023	75.3M	81.5M	82.8M	81.1M
2022	55.2M	59.9M	65.5M	71.3M
2021	33.0M	38.3M	43.6M	49.0M
2020	0	0	0	27.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sight Sciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	hayden jeremy b.	sold	-24,851	5.079	-4,893	chief legal officer
Apr 03, 2024	bauerlein alison	sold	-51,414	5.079	-10,123	chief financial officer
Apr 03, 2024	park sam boong	sold	-17,339	5.079	-3,414	chief operating officer
Apr 03, 2024	badawi paul	sold	-63,848	5.079	-12,571	president and ceo
Apr 03, 2024	badawi david	sold	-15,887	5.079	-3,128	chief technology officer
Feb 14, 2024	hayden jeremy b.	sold	-	-	-151,869	chief legal officer
Feb 14, 2024	bauerlein alison	sold	-	-	-315,421	chief financial officer
Feb 14, 2024	park sam boong	sold	-	-	-151,869	chief operating officer
Feb 14, 2024	badawi paul	sold	-	-	-390,187	president and ceo
Feb 14, 2024	badawi david	sold	-	-	-108,645	chief technology officer

Which funds bought or sold SGHT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-83.92	-304,086	59,880	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-6,881	11,473	-%
May 15, 2024	Engineers Gate Manager LP	new	-	60,382	60,382	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	62,536	62,536	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	378	999,382	1,255,930	-%
May 15, 2024	Palo Alto Investors LP	sold off	-100	-896,756	-	-%
May 15, 2024	MARSHALL WACE, LLP	sold off	-100	-245,167	-	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	sold off	-100	-53,432	-	-%
May 15, 2024	RTW INVESTMENTS, LP	sold off	-100	-850,399	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-89.97	-55,918	6,394	-%

Are Funds Buying or Selling SGHT?

Are funds buying SGHT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SGHT

No. of Funds

Unveiling Sight Sciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	kck ltd.	9.5%	4,646,866	SC 13G/A
Feb 13, 2024	bank of america corp /de/	6.5%	3,174,134	SC 13G
Feb 07, 2024	ubs group ag	5.9%	2,879,863	SC 13G
Jan 10, 2024	d1 capital partners l.p.	0%	0	SC 13G/A
Dec 01, 2023	encrantz staffan	8.3%	4,022,118	SC 13D/A
Feb 14, 2023	hep partners llc	0.0%	0	SC 13G/A
Feb 14, 2023	badawi paul	11.8%	5,691,953	SC 13G/A
Feb 13, 2023	kck ltd.	9.9%	4,776,232	SC 13G
May 19, 2022	encrantz staffan	8.5%	4,022,118	SC 13D/A
Apr 18, 2022	shd gp ii, llc	0.55%	262,695	SC 13D/A

Recent SEC filings of Sight Sciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 06, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading

Peers (Alternatives to Sight Sciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Sight Sciences, Inc. News

Latest updates

Sight Sciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	2.7%	19,265,000	18,751,500	20,009,000	23,471,000	18,824,000	20,543,500	18,677,000	17,229,000	14,881,000	14,685,000	13,101,000	12,535,000	8,635,000	8,643,000	8,651,000	3,502,000
Gross Profit	3.1%	16,472,000	15,976,000	17,332,000	20,090,000	15,776,000	16,879,000	15,749,000	14,493,000	11,848,000	12,743,000	11,039,000	10,230,000	6,334,000	-	6,031,000	1,417,000
Operating Expenses	15.2%	31,195,000	27,085,000	30,743,000	35,277,000	33,344,000	33,931,500	37,594,000	37,357,000	34,041,000	27,459,000	25,069,000	21,306,000	17,990,000	-	13,386,000	9,107,000
S&GA Expenses	12.3%	26,559,000	23,658,000	26,504,000	30,056,000	28,675,000	28,698,000	31,541,000	31,431,000	28,395,000	23,090,000	20,790,000	17,760,000	14,550,000	-	11,228,000	7,664,000
R&D Expenses	35.3%	4,636,000	3,427,000	4,239,000	5,221,000	4,669,000	5,233,500	6,053,000	5,926,000	5,646,000	4,369,000	4,279,000	3,546,000	3,440,000	-	2,158,000	1,443,000
EBITDA Margin	2.0%	-0.60	-0.61	-0.67	-0.80	-0.99	-1.14	-1.22	-1.25	-1.25	-1.18	-0.72	-0.83	-0.96	-	-	-
Interest Expenses	-10.9%	1,204,000	1,351,000	1,432,000	1,349,000	1,276,000	1,223,500	1,131,000	1,065,000	1,046,000	1,078,000	1,122,000	1,082,000	1,084,000	-	538,000	549,000
Income Taxes	70.0%	17,000	10,000	78,000	8,000	14,000	10,000	19,000	9,000	9,000	98,000	16,000	22,000	52,000	-	8,000	6,000
Earnings Before Taxes	-52.1%	-16,249,000	-10,681,000	-12,957,000	-14,746,000	-17,053,000	-16,897,000	-22,210,000	-23,834,000	-23,254,000	-15,838,000	-17,153,000	-17,593,000	-12,188,000	-	-8,089,000	-8,310,000
EBT Margin	2.0%	-0.67	-0.68	-0.74	-0.87	-1.06	-1.21	-1.30	-1.34	-1.34	-1.28	-0.79	-0.90	-1.05	-	-	-
Net Income	-52.5%	-16,300,000	-10,691,000	-13,035,000	-14,754,000	-17,067,000	-16,907,000	-22,229,000	-23,843,000	-23,263,000	-15,936,000	-17,169,000	-17,615,000	-12,240,000	-9,105,000	-8,097,000	-8,316,000
Net Income Margin	1.9%	-0.67	-0.69	-0.75	-0.87	-1.06	-1.21	-1.30	-1.34	-1.34	-1.29	-1.29	-1.23	-1.15	-	-	-
Free Cashflow	-46.8%	-9,903,000	-6,748,000	-10,132,000	-13,586,000	-17,509,000	-15,631,000	-20,464,000	-18,647,000	-22,193,000	-10,879,000	-16,799,000	-12,701,000	-12,974,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-6.7%	156	167	177	185	197	213	225	241	259	280	291	53.00	73.00
Current Assets	-6.6%	152	163	174	182	194	210	222	238	255	277	288	47.00	71.00
Cash Equivalents	-7.9%	127	138	145	155	167	185	200	220	239	261	271	36.00	62.00
Inventory	-12.5%	7.00	8.00	9.00	8.00	7.00	6.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00
Net PPE	-5.5%	2.00	2.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
Liabilities	-0.2%	46.00	46.00	50.00	49.00	50.00	53.00	52.00	49.00	47.00	48.00	45.00	52.00	44.00
Current Liabilities	-4.6%	12.00	12.00	14.00	14.00	15.00	18.00	17.00	14.00	12.00	14.00	10.00	12.00	9.00
Long Term Debt	6.3%	34.00	32.00	34.00	34.00	33.00	33.00	33.00	33.00	33.00	33.00	32.00	32.00	32.00
LT Debt, Current	-100.0%	-	2.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	32.00	34.00	34.00	33.00	33.00	33.00	33.00	33.00	33.00	32.00	32.00	32.00
Shareholder's Equity	-9.2%	109	120	127	136	146	160	173	192	212	232	246	-	-
Retained Earnings	-5.5%	-311	-294	-284	-271	-256	-239	-222	-200	-176	-153	-137	-119	-90.04
Additional Paid-In Capital	1.3%	420	415	411	407	403	399	395	392	388	385	383	3.00	1.00
Shares Outstanding	0.9%	50.00	49.00	48.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	40.00	10.00	-
Float	-	-	-	-	302	-	-	-	290	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-50.9%	-9,786	-6,484	-9,828	-13,489	-17,383	-15,502	-20,192	-18,305	-21,966	-10,722	-16,512	-12,436	-12,870	-	-	-
Share Based Compensation	30.2%	4,506	3,460	3,856	3,742	3,523	3,234	3,223	3,532	2,974	1,976	1,899	931	277	-	-	-
Cashflow From Investing	55.7%	-117	-264	-304	-97.00	-126	-129	-272	-342	-227	-157	-287	-265	-104	-	-	-
Cashflow From Financing	-350.5%	-942	376	118	766	-156	812	186	158	92.00	91.00	252,702	-54.00	-210	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SGHT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 19,265	$ 18,824
Cost of goods sold	2,793	3,048
Gross profit	16,472	15,776
Operating expenses:
Research and development	4,636	4,669
Selling, general and administrative	26,559	28,675
Total operating expenses	31,195	33,344
Loss from operations	(14,723)	(17,568)
Investment income	1,648	1,810
Interest expense	(1,204)	(1,276)
Loss on debt extinguishment	(1,962)	0
Other expense, net	(8)	(19)
Loss before income taxes	(16,249)	(17,053)
Provision for income taxes	17	14
Net loss attributable to common stockholders	$ (16,266)	$ (17,067)
Net loss per share attributable to common stockholders-basic	$ (0.33)	$ (0.35)
Net loss per share attributable to common stockholders-diluted	$ (0.33)	$ (0.35)
Weighted-average shares used in computing net loss per share attributable to common stockholders-basic	49,486,263	48,405,271
Weighted-average shares used in computing net loss per share attributable to common stockholders-diluted	49,486,263	48,405,271

SGHT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 127,284	$ 138,129
Accounts receivable, net of allowance for credit losses of $1,019 and $1,186 at March 31, 2024 and December 31, 2023, respectively	15,643	14,289
Inventory, net	6,871	7,849
Prepaid expenses and other current assets	2,291	2,604
Total current assets	152,089	162,871
Property and equipment, net	1,550	1,640
Operating lease right-of-use assets	1,297	1,458
Other noncurrent assets	624	682
Total assets	155,560	166,651
Current liabilities:
Accounts payable	1,666	1,731
Accrued compensation	4,028	4,528
Accrued and other current liabilities	5,999	3,774
Current portion - long-term debt, net	0	2,219
Total current liabilities	11,693	12,252
Long-term debt	33,697	31,708
Other noncurrent liabilities	961	2,476
Total liabilities	46,351	46,436
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, par value of $0.001 per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2024, respectively; 49,565,200 and 49,131,363 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	50	49
Additional paid-in-capital	420,215	414,956
Accumulated deficit	(311,056)	(294,790)
Total stockholders' equity	109,209	120,215
Total liabilities and stockholders' equity	$ 155,560	$ 166,651

About Sight Sciences, Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

CEO	Mr. Paul Badawi
WEBSITE	sightsciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	250

Sight Sciences, Inc. Frequently Asked Questions

What is the ticker symbol for Sight Sciences, Inc.? What does SGHT stand for in stocks?

SGHT is the stock ticker symbol of Sight Sciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sight Sciences, Inc. (SGHT)?

As of Fri May 17 2024, market cap of Sight Sciences, Inc. is 265.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGHT stock?

You can check SGHT's fair value in chart for subscribers.

What is the fair value of SGHT stock?

You can check SGHT's fair value in chart for subscribers. The fair value of Sight Sciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sight Sciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGHT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sight Sciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SGHT is over valued or under valued. Whether Sight Sciences, Inc. is cheap or expensive depends on the assumptions which impact Sight Sciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGHT.

What is Sight Sciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SGHT's PE ratio (Price to Earnings) is -4.85 and Price to Sales (PS) ratio is 3.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGHT PE ratio will change depending on the future growth rate expectations of investors.